Outcomes for COPD pharmacological trials: From lung function to biomarkers

M. Cazzola, W. MacNee, F. J. Martinez, K. F. Rabe, L. G. Franciosi, P. J. Barnes, V. Brusasco, P. S. Burge, P. M.A. Calverley, B. R. Celli, P. W. Jones, D. A. Mahler, B. Make, M. Miravitlles, C. P. Page, P. Palange, D. Parr, M. Pistolesi, S. I. Rennard, M. P. Rutten-van MölkenR. Stockley, S. D. Sullivan, J. A. Wedzicha, E. F. Wouters

Research output: Contribution to journalReview articlepeer-review

720 Scopus citations


The American Thoracic Society/European Respiratory Society jointly created a Task Force on "Outcomes for COPD pharmacological trials: from lung function to biomarkers" to inform the chronic obstructive pulmonary disease research community about the possible use and limitations of current outcomes and markers when evaluating the impact of a pharmacological therapy. Based on their review of the published literature, the following document has been prepared with individual sections that address specific outcomes and markers, and a final section that summarises their recommendations. Copyright

Original languageEnglish (US)
Pages (from-to)416-468
Number of pages53
JournalEuropean Respiratory Journal
Issue number2
StatePublished - Feb 2008

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine


Dive into the research topics of 'Outcomes for COPD pharmacological trials: From lung function to biomarkers'. Together they form a unique fingerprint.

Cite this